Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2018 · 10-Q
Revenue—
Net Income-$5.00M-$5.00MN/M vs Q2 2017 EPS Diluted-$0.53-$0.53N/M vs Q2 2017 Operating Income-$4,994,000N/M Operating Cash Flowderived-$1,875,800N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end